HYDERGINE INJ

Co-Dergocrine Mesylate Injection works by interacting with dopamine receptors in the brain. It is a combination of two substances, dihydroergocornine and dihydroergocristine, which are derived from ergot alkaloids. This combination has a unique effect on dopamine metabolism, modulating both pre• and post-synaptic dopamine receptors. Dihydroergocornine acts as a dopamine agonist, stimulating dopamine receptors, while dihydroergocristine has a regulatory effect on dopamine synthesis and release. Together, they help to improve dopamine-related neurotransmission, which is believed to contribute to its therapeutic benefits in various dopamine-related conditions. The mechanism involves enhancing dopamine-mediated neuronal activity, promoting dopamine synthesis, and regulating dopamine receptor sensitivity.

Co-Dergocrine Mesylate

Gonadotropin-releasing hormone analog.

Injection

The following are the uses of Co-Dergocrine Mesylate Injection:

• Used for improving cognitive function and memory in postmenopausal women.
• Used for treating age-related memory decline and enhancing overall mental performance.
• Used for managing symptoms of menopause, particularly hot flashes and mood changes.
• Used for alleviating vaginal dryness and discomfort associated with hormonal changes.
• Used for supporting overall well-being and vitality during the menopausal transition.
• Used for potentially reducing the risk of osteoporosis by preserving bone density.
• Used for managing certain types of depression related to hormonal imbalances.
• Used for restoring hormonal balance and relieving menopausal-related sleep disturbances.

In the case of an overdose of Co-Dergocrine Mesylate Injection, immediate medical intervention is necessary. Symptoms may include severe dizziness, fainting, rapid heartbeat, and potentially life-threatening complications. It is crucial to contact a healthcare professional or go to the nearest emergency room for prompt treatment. They will provide supportive care and monitor vital signs to ensure the patient's safety and manage any adverse effects effectively.

In the case of a missed dose of Co-Dergocrine Mesylate Injection, it is important to act promptly. If you remember within a few hours of the missed dose, administer the injection as soon as possible. However, if a significant amount of time has passed or if it is close to the time for your next scheduled dose, it is best to skip the missed dose and continue with your regular dosing schedule. Do not double the dose to make up for a missed one, as this may increase the risk of side effects. Consult your healthcare provider if you have any concerns or if you miss multiple doses.

To administer Co-Dergocrine Mesylate Injection, clean the injection site with an alcohol swab, insert the needle at a 90-degree angle, and slowly inject the prescribed dosage as directed by your healthcare provider, ensuring the entire volume is administered subcutaneously or intramuscularly as instructed.

Following are the conditions/situations when Co-Dergocrine Mesylate Injection should not be administered:

• Allergic reactions • Should not be used if the patient has a known allergy or hypersensitivity to Co-Dergocrine Mesylate or any of its components.
• Pregnancy and breastfeeding • Contraindicated in pregnant women and breastfeeding mothers.
• Undiagnosed vaginal bleeding • Not recommended for women with undiagnosed vaginal bleeding.
• Thromboembolic disorders • Should not be used in patients with a history of blood clots or thromboembolic disorders.
• Cardiovascular disease • Contraindicated in individuals with severe cardiovascular diseases, including coronary artery disease, stroke, or uncontrolled hypertension.
• Liver impairment • Not suitable for patients with active liver disease or impaired liver function.
• Pituitary tumors • Should not be administered to individuals with pituitary tumors or a history of pituitary gland disorders.
• Postpartum period • Not recommended during the postpartum period, especially in women with a history of thromboembolic events.

The possible side effects of Co-Dergocrine Mesylate Injection may include:

• Allergic reactions such as skin rash, itching, or hives.
• Increased heart rate or palpitations.
• Dizziness or lightheadedness.
• Headaches.
• Nausea and vomiting.
• Weight gain or swelling due to fluid retention.
• Changes in blood pressure (either increase or decrease).
• Breast tenderness or enlargement.

Following are the precautions and warnings for Co-Dergocrine Mesylate Injection:

• This medication should not be used in patients with a known allergy or hypersensitivity to Co-Dergocrine Mesylate or any of its components.
• It is important to inform your doctor about any other medications or supplements you are taking to avoid potential drug interactions.
• Patients with a history of liver or kidney disease should use this medication with caution and under close medical supervision.
• Co-Dergocrine Mesylate may cause dizziness or drowsiness; patients should avoid driving or operating heavy machinery until they know how the medication affects them.
• This injection should be administered by trained medical professionals only, and the recommended dosage should not be exceeded.
• Pregnant and breastfeeding women should consult their doctor before using this medication, as the risks and benefits should be carefully evaluated.
• In case of any unusual symptoms or severe side effects, medical attention should be sought immediately.
• Store the injection as directed, away from direct sunlight and moisture, and keep out of reach of children.

Following are the drug interactions for Co-Dergocrine Mesylate Injection:

• Co-administration with drugs that affect blood pressure, such as antihypertensives, may require dose adjustments to maintain desired blood pressure levels.
• It can interact with anticoagulants, increasing the risk of bleeding. Close monitoring is necessary.
• When used with other medications that affect the central nervous system, like sedatives or opioids, it may enhance their effects, requiring dosage adjustments.
• Co-Dergocrine may increase the effects of anti-diabetic medications, potentially leading to hypoglycemia. Regular blood sugar monitoring is advised.
• Drugs that induce or inhibit liver enzymes, such as certain antibiotics or antifungals, may alter the metabolism of Co-Dergocrine.
• Combining with other hormones or hormone-modulating drugs might result in unpredictable hormonal effects.
• Caution is warranted when using Co-Dergocrine with herbal supplements, especially those affecting hormone levels or blood clotting.

Following are the food interactions for Co-Dergocrine Mesylate Injection:

• Alcohol consumption should be avoided as it may cause excessive sedation and potentiate the central nervous system effects of Co-Dergocrine, leading to increased dizziness, drowsiness, and impaired coordination.
• Grapefruit and its juice are to be avoided as they can interfere with the metabolism of Co-Dergocrine, potentially increasing its blood levels and the risk of side effects, particularly on the cardiovascular system.
• High-fat meals might affect the absorption of Co-Dergocrine, possibly leading to increased side effects or reduced effectiveness. It is advisable to maintain a consistent dietary pattern while taking this medication.
• Caffeine intake should be monitored as it can interact with the central nervous system effects of Co-Dergocrine, potentially causing increased anxiety, nervousness, or sleep disturbances.
• Salt and potassium-rich foods are recommended as Co-Dergocrine may affect electrolyte balance, and maintaining adequate levels is crucial for overall health.
• Staying well-hydrated is essential, especially with increased fluid intake to support overall health and ensure the proper functioning of the circulatory system.
• There are no direct food interactions that significantly impact the absorption of Co-Dergocrine, but it is always advisable to consult with a healthcare professional for personalized advice based on your medical history and current medications.
• Always adhere to the dietary guidelines provided by your healthcare provider to ensure the optimal effectiveness of Co-Dergocrine Mesylate Injection.

Storage and Disposal of Co-Dergocrine Mesylate Injection should be handled with care to maintain its integrity and ensure safety. Store the injection in a cool, dry place, preferably at room temperature, and protect it from direct sunlight and heat sources to maintain its potency. Keep the injection in its original packaging, ensuring the seal remains intact, to prevent contamination. Always check the expiration date before use, and dispose of expired or unused injections promptly. Do not dispose of the medication by flushing or pouring it down the drain; instead, follow local guidelines or consult a pharmacist for safe disposal methods. Keep the injection out of children's reach to prevent accidental exposure.

Following are the quick tips for Co-Dergocrine Mesylate Injection:

• Administer the injection under medical supervision for accurate dosage and safe administration.
• Ensure the injection is stored at the appropriate temperature, as directed by the pharmacist.
• Clean the injection site with an antiseptic before administration to reduce the risk of infection.
• Rotate injection sites to minimize discomfort and potential tissue damage.
• Dispose of used needles and syringes safely in designated sharps containers.
• Avoid missing doses to maintain consistent medication levels in the body.
• Inform your doctor if you experience any unusual symptoms or side effects.
• Keep a record of your injection dates and dosage for reference.